Munich - Delayed Quote EUR

TME Pharma NV (0N6A.MU)

Compare
0.0752
0.0000
(0.00%)
As of 8:06:35 AM GMT+1. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 0N6A.MU

Recent News: 0N6A.MU

View More
TME Pharma Announces Collaboration with aimed analytics for AI-Driven Drug Discovery and Optimization

TME Pharma Announces Collaboration with aimed analytics for AI-Driven Drug Discovery and Optimization
Business Wire 2 days ago
TME Pharma Announces Successful Completion of €2.6 Million Public Offer With Strong Shareholder Support

TME Pharma Announces Successful Completion of €2.6 Million Public Offer With Strong Shareholder Support
Business Wire last month
TME Pharma Provides Results of Fourth Exercise of Warrants Z

TME Pharma Provides Results of Fourth Exercise of Warrants Z
Business Wire last month
TME Pharma Announces the Launch of Fully Guaranteed Public Offer for €2.6 Million Open Only to Shareholders to Enable Completion of Strategic Transactions by June 2025

TME Pharma Announces the Launch of Fully Guaranteed Public Offer for €2.6 Million Open Only to Shareholders to Enable Completion of Strategic Transactions by June 2025
Business Wire last month
CORRECTING and REPLACING: TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of Transactions ...

CORRECTING and REPLACING: TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of Transactions ...
Business Wire last month
TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of Transactions Around NOX-A12 and NOX-E36 by June 2025

TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of Transactions Around NOX-A12 and NOX-E36 by June 2025
Business Wire last month
TME Pharma Announces Poster Presentation by U.S. National Cancer Institute on CXCL12 Inhibition by NOX-A12 in Glioblastoma at 2024 SNO Annual Meeting

TME Pharma Announces Poster Presentation by U.S. National Cancer Institute on CXCL12 Inhibition by NOX-A12 in Glioblastoma at 2024 SNO Annual Meeting
Business Wire 2 months ago
TME Pharma Awarded €2.4 Million German Federal Grant to Support NOX-A12 Phase 2 Trial in Brain Cancer

TME Pharma Awarded €2.4 Million German Federal Grant to Support NOX-A12 Phase 2 Trial in Brain Cancer
Business Wire 2 months ago
TME Pharma Reports H1 2024 Financial Results and Provides Business and Clinical Update

TME Pharma Reports H1 2024 Financial Results and Provides Business and Clinical Update
Business Wire 3 months ago
TME Pharma Announces Appointment of Alexandra Glucksmann to Supervisory Board

TME Pharma Announces Appointment of Alexandra Glucksmann to Supervisory Board
Business Wire 3 months ago
TME Pharma Provides Results of Third Exercise of Warrants Z

TME Pharma Provides Results of Third Exercise of Warrants Z
Business Wire 4 months ago
View More

Related Tickers

OVIT OncoVista Innovative Therapies, Inc.
0.0002
0.00%
 
VICO.ST Vicore Pharma Holding AB (publ)
9.05
-1.20%
 
RPRX Royalty Pharma plc
31.38
-0.66%
 
SMMT Summit Therapeutics Inc.
22.49
+0.56%